Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 1CM Inc C.EPIC

Alternate Symbol(s):  MILFF

Healthcare Cannabis
1CM Inc. is a Canada-based multi-jurisdictional company. The Company is focused on cannabis and other complementary and substitutable vice retail industries including liquor, tobacco, and nicotine. It’s One Cannabis Market, is a technology platform that provides business-to-business (B2B) and business-to- consumer (B2C) Solutions including Last Mile Delivery, Digital Signage, Big Data Analytics... see more

Recent & Breaking News (CSE:EPIC)

MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017

Accesswire August 3, 2017

Adhoc: MorphoSys Announces that Its Partner, Bayer, Reports on Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma

Accesswire July 21, 2017

MorphoSys Announces that Its Partner, Bayer, Reports on Phase 2 Study of Investigational Anetumab Ravtansine in Second-Line Mesothelioma

Accesswire July 21, 2017

MorphoSys Announces that Its Licensee, Janssen, Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Accesswire July 13, 2017

MorphoSys to Host Q2 2017 Conference Call on August 3, 2017

Accesswire July 13, 2017

MorphoSys Celebrates 25th Anniversary

Accesswire July 6, 2017

MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at ASCO 2017

Accesswire June 5, 2017

MorphoSys Presents First Safety and Efficacy Data of MOR208 in Combination with Lenalidomide from a Phase 2 Study in DLBCL

Accesswire June 5, 2017

MorphoSys Starts Phase 3 Trial of MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL

Accesswire June 2, 2017

MorphoSys Announces That Its Licensee Janssen Reported Updates on the Development of Guselkumab

Accesswire May 24, 2017

MorphoSys to Present at Three Upcoming Conferences

Accesswire May 24, 2017

MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers

Accesswire May 19, 2017

MorphoSys to Present Clinical Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2017

Accesswire May 18, 2017

MorphoSys AG Reports Outcome of Annual General Meeting 2017

Accesswire May 17, 2017

MorphoSys Partner to Start Phase 2 Trial with Bimagrumab in Obese Patients with Type 2 Diabetes

Business Wire January 12, 2017

Dr. Malte Peters to Become New Chief Development Officer of MorphoSys AG

Business Wire January 5, 2017

MorphoSys to Present at Upcoming Investor Conferences

Business Wire January 3, 2017

MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatology

GlobeNewswire November 2, 2016

MorphoSys to Host Q3 2016 Conference Call on November 7, 2016

GlobeNewswire October 28, 2016

MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody

GlobeNewswire October 20, 2016